101. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using
- Author
-
Byung-Soo, Kim, Won-Ku, Lee, Kyoungjune, Pak, Junhee, Han, Gun-Wook, Kim, Hoon-Soo, Kim, Hyun-Chang, Ko, Moon-Bum, Kim, and Seong-Jang, Kim
- Subjects
Adult ,Inflammation ,Male ,Vasculitis ,Adolescent ,Middle Aged ,Severity of Illness Index ,Young Adult ,Liver ,Fluorodeoxyglucose F18 ,Case-Control Studies ,Positron Emission Tomography Computed Tomography ,Feasibility Studies ,Humans ,Psoriasis ,Female ,Ustekinumab ,Dermatologic Agents ,Radiopharmaceuticals ,Aorta ,Spleen ,Aged - Abstract
Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease.To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured usingPatients with psoriasis and healthy controls underwent baselineAfter a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P .05).Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population.Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.
- Published
- 2017